ACTRN12611000854932已完成1 期
A Randomised, Placebo Controlled, Double-Blind, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1103 in Healthy Adult Male Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 45 Years（—）
- 性别
- Male
入选标准
- •1. Aged from 18 years up to 45 years (inclusive).
- •3. Body Mass Index (BMI) BMI of 19 to 30 kg/m2 with body weight of between 70kg and 90kg.
- •4. Healthy as determined by a medical history
- •5. Serum IGF-1 levels within the normal range
- •6. Adequate venous access
- •7. Fluent in the English language.
- •8. Written informed consent.
排除标准
- •Volunteers with any of the following criteria will not be eligible for participation in this study:
- •1. Hypersensitivity. History of allergy and/or hypersensitivity to any of the stated ingredients of the formulations. A known hypersensitivity to lidocaine or all surgical dressings which may be used in the study procedures.
- •2. Medical Conditions
- •a) History of clinically significant gastrointestinal, hepatic, renal, cardiovascular, dermatological, immunological, respiratory, endocrine, oncological, neurological, metabolic, psychiatric disease or haematological disorders.
- •b) Any history of clinically significant cardiac arrhythmias or the presence of clinically significant abnormalities on ECG at Screening.
- •c) Any evidence or history of hypotension or hypertension in the opinion of the PI following repeat assessment.
- •d) Any history of asthma during the last 10 years.
- •e) A calculated creatinine clearance of less than 75 mL/min.
- •f) Any predisposing condition that in the opinion of the Investigator might interfere with the absorption, distribution, metabolism and/or excretion of drugs.
- •g) History of abnormal bleeding tendencies or thrombophlebitis unrelated to venepuncture or intravenous cannulation, or a history of Hepatitis B, a positive test for Hepatitis B surface antigen, a history of Hepatitis C, a positive test for Hepatitis C antibody, a history of HIV infection or demonstration of HIV antibodies.
- •h) Inability to tolerate repeated venepuncture.
- •3. Laboratory Status. Any evidence of organ dysfunction, or any deviation in clinical laboratory values which is confirmed upon re-examination to be clinically significant (i.e., in the opinion of the PI would jeopardise the safety of the subject or impact on the validity of the study results), including a liver function test (LFT) > upper limit of normal (ULN). Total bilirubin levels > 1.5 x ULN will be allowed if associated with Gilbert’s syndrome.
- •4. Ethanol Use. Regular drinkers of more than four (4) units of alcohol daily (1 unit = 300 mL beer, 1 glass wine, 1 measure spirit) or those who may have difficulty abstaining from alcohol during the 48 hours prior to dose administration and until completion of blood sampling on Day 2 for the single-dose cohorts (Stage A) or Day 7 for the multiple-dose cohorts (Stage B).
- •5. Drug and Alcohol Abuse. History of, or current evidence of, abuse of alcohol or any drug substance, licit or illicit, or positive urine drug and alcohol screen for drugs of abuse and alcohol.
- •6. Smoking. Current smoker of not more than 5 cigarettes or equivalent per day prior to commencing the study, unable to completely stop smoking during the study.
- •7. Medication
- •a) Difficulty in abstaining from any prescription medications for 14 days prior to dose administration and for the duration of the study.
- •b) Difficulty in abstaining from over-the-counter (OTC) medications or herbal supplements for seven days prior to dose administration and for the duration of the study.
- •8. Administration site. Any tattoos in the anterior abdominal area which, in the opinion of the Investigator would preclude accurate local tolerance assessments of injection sites.
- •9. Xanthine Use. Difficulty in abstaining from food and/or beverages that contain caffeine or other xanthines
- •(e.g., coffee, tea, cola and chocolate) during the 24 hours prior to dose administration and whilst confined at the clinical facility.
- •10. Psychiatric or Psychological Disorder.History of any psychi
研究者
相似试验
已完成
1 期
A Randomised, Placebo-Controlled, Double-Blind, Single Dose Escalation Study to evaluate the Safety, Tolerability and Pharmacokinetics of Betahistine Dihydrochloride Following a Single Intranasal Dose in Healthy Male and Female Volunteers.OME (Otitis Media with Effusion)Ear - Other ear disordersACTRN12613000892718Otifex Therapeutics Pty Ltd24
已完成
1 期
Safety and pharmacokinetic study of ACV1, a potential neuropathic pain treatment.europathic painNeuropathic painNeurological - Other neurological disordersACTRN12605000408684Metabolic Pharmaceuticals Ltd.60
已完成
不适用
To Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge ModelDiseases of th respiratory systemKCT0001180Celltrion81
已完成
不适用
A Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food on the Pharmacokinetics of DRL-17822 in Healthy Adult Male Volunteerscoronary heart disease10011082AtherosclerosisNL-OMON33454Dr. Reddy's Laboratories Ltd.72
招募中
不适用
A Randomised, Double-Blind, Placebo-Controlled, Single- and Multiple-, Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of VRG50635 and Food Effect in Healthy Volunteers (Phase 1a)Amyotrophic lateral sclerosis10041543NL-OMON56052Verge Genomics84